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EssentialsHemophilia A (HA) is a bleeding disorder caused by the deficiency of coagulation factor VIII (FVIII).The main treatment‐related complication in patients with HA is the development of inhibitor.Inhibitors are alloantibodies that neutralize the procoagulant activity of infused FVIII.The reasons why only 20%‐30% of the patients with HA develop inhibitors remain a challenge.
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